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In addition to intrinsic resistance in Acinetobacter baumannii, many different types of acquired resistance
mechanisms have been reported, including the presence of VIM and IMP metallo b-lactamases and also of
blaOXA-23-like and blaOXA-58-like enzymes. In the Kurdistan region of Iraq, the multiresistant A. baumannii--
calcoaceticus complex is prevalent. We characterized the different mechanisms of resistance present in clinical
isolates collected from different wards and different hospitals from the Kurdistan region. One hundred twenty
clinical nonduplicate A. baumannii-calcoaceticus complex isolates were collected from four hospitals between
January 2012 and October 2013. The identification of the isolates was confirmed by MALDI-TOF. The suscep-
tibility to different antibiotics was determined by disk diffusion and analyzed in accordance to EUCAST guide-
lines. By PCR, the presence of blaOXA-51-like, blaOXA-23-like, blaOXA-24-like, and blaOXA-58-like genes was determined
as well as the presence of the insertion element ISAba1. Clonal diversity was analyzed by pulsed-field gel
electrophoresis (PFGE) using the restriction enzyme ApaI and, in addition, multilocus sequence typing (MLST)
was performed on a selected subset of 15 isolates. All 120 A. baumannii isolates harbored blaOXA-51-like genes. One
hundred one out of 110 (92%) imipenem (IMP)-resistant A. baumannii-calcoaceticus complex isolates additionally
carried the blaOXA-23-like gene and four isolates (3%) were positive for blaOXA-24-like. All 101 blaOXA-23-like-positive
isolates had the ISAba1 insertion sequence, 1,600 bp upstream of the blaOXA-23-like gene. The blaOXA-58-like gene
was not detected in any of the 110 IMP-resistant strains. Eight different PFGE clusters were identified and distributed
over the different hospitals. MLST analysis performed on a subset of 15 representative isolates revealed the presence
of the international clone ST2 (Pasteur). Besides ST2 (Pasteur), also many other STs (Pasteur) were encountered such
as ST136, ST94, ST623, ST792, and ST793, all carrying the blaOXA-23 gene. In clinical A. baumannii-calcoaceticus
complex isolates from Kurdistan-Iraq, the blaOXA-23 gene in combination with the upstream ISAba1 insertion
element is largely responsible for carbapenem resistance. Several small clusters of identical genotypes were found
from patients admitted to the same ward and during overlapping time periods, suggesting transmission within the
hospital. Identification of source(s) and limiting the transmission of these strains to patients needs to be prioritized.
Keywords: A. Baumannii-calcoaceticus complex, OXA-23, ISAba1, multi-resistance, carbapenemases, clonal
relationship
Introduction
Acinetobacter baumannii is an important opportunisticnosocomial pathogen.1,2 Infections caused by A. bau-
mannii are difficult to treat because of its intrinsic resistance to
various classes of antibiotics and its ability to acquire addi-
tional resistance.3,4 Due to these characteristics, A. baumannii
is included in the so-called group of ESKAPE organisms.5
The carbapenem antibiotics play an important role in
the treatment of A. baumannii6 infections. However, A.
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baumannii can also become resistant to carbapenems through
a number of mechanisms, including the presence of metallo-
beta-lactamases (class B) or the presence and overexpres-
sion of OXA-type carbapenemases (class D).7 Especially,
blaOXA-23-like, blaOXA-24-like, blaOXA-58-like b-lactamases are
often demonstrated in addition to the intrinsic presence of
blaOXA-51 in carbapenem-resistant A. baumannii.
8,9 These ad-
ditional OXA resistance genes are often accumulated in large
resistance islands, located in a region prone to insertion and
deletion within the bacterial chromosome.10 The presence
of the blaoxa-51-like gene does not usually result in increased
MICs for carbapenems, this in contrast to, for instance, the
blaOXA-23-like genes. The expression levels of these additional
blaOXA-23-like genes are often regulated by an upstream inser-
tion sequence (ISAba1) resulting in increased MICs for car-
bapenems.3,11
These multidrug- and pandrug-resistant strains of A.
baumannii are increasingly reported worldwide and pose a
serious concern for healthcare,12,13 In most Western Euro-
pean hospitals, the prevalence of multidrug-resistant (MDR)
A. baumannii is limited and only found during local out-
breaks. However, OXA-23 was recently shown to increase
in frequency in Italy, Greece, and Turkey.14–18 The in-
creasing prevalence of A. baumannii is not only described in
Europe but also OXA-23 has been reported in the United
States as the most prevalent mechanism of resistance in
Acinetobacter baumannii-calcoaceticus complex isolates.19
Besides its increasing prevalence, these outbreaks are mainly
linked to the worldwide spread of successful clones, such as
international clones I and II,20 CCI (comprising ST1, ST7,
ST8, ST19, and ST20), CC2 (comprising ST2, ST45, and
ST47, Pasteur typing scheme).21 However, OXA-23 is also
increasingly found in other multilocus sequence types such as
ST15 and ST25.20
The report from Hujer et al. from 2006 suggested that
MDR Acinetobacter sp. were present in Iraq, including iso-
lates with OXA-23-like and OXA-58-like, as these were
found among patients whowere injured in Iraq orAfghanistan
and then treated in the United States.22 Currently, the wounds
resulting from burn injuries are frequently colonized with
A. baumannii-calcoaceticus complex, but also A. baumannii-
calcoaceticus complex is cultured from other specimens from
patients with different underlying diseases. As epidemiolog-
ical surveillance is not generally practiced in Iraqi hospitals,
we collected in the present study 120 MDR A. baumannii-
calcoaceticus complex isolates deriving from different hos-
pitals in the region of Kurdistan. The aim was to characterize
themechanism of carbapenem resistance and to determine the
clonal relatedness among the different carbapenem-resistant
A. baumannii-calcoaceticus complex isolates.
Materials and Methods
Bacterial isolates and identification
Isolates from clinical specimens, including urine, wounds,
blood, sputum, and few other sources, were collected. The
isolates were collected from January 2012 to October 2013
in the Rizgari teaching hospital, Rozhawa teaching hospital,
and Hawler teaching hospital, all located in the city of Erbil,
Iraq (Fig. 1). Additional specimens were collected from the
Sulaymaniyah teaching hospital located at Slemani city. The
isolates included in the present study were all derived from
patients admitted >48hrs to the hospital. The isolates were ini-
tially identified byVITEK2 (bioMe´rieux). The primary obtained
identification was confirmed bymatrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOFMS)
by making use of the Biotyper system (Bruker Daltonics) and
analyzed by software versionV4.0.0.1_4613-5627. The patient’s
social and demographic information, including age, gender, and
hospital status, was recorded.
Antimicrobial susceptibility testing
Antimicrobial susceptibility was determined for imipe-
nem,meropenem, ceftazidime, ciprofloxacin, and tobramycin
by disk diffusion and was performed according to the EU-
CAST guidelines.23
DNA preparation from bacteria
Genomic DNA of all organisms was extracted by sus-
pending colonies from a blood agar plate into DNA extraction
reagent of the InstaGene matrix commercial reagent kit.
The DNA extraction procedure was subsequently performed
in accordance with the guidelines of the InstaGene Matrix
(Biorad). The extracted DNA was kept at -20C until am-
plification.
PCR amplification
The extracted DNA of the isolates was subjected to PCR
to detect blaOXA-51-like, blaOXA-23-like, blaOXA-24-like, and
blaOXA-58-like and ISAba1. The upstream location of the
ISAba1 insertion element of the different blaOXA genes was
demonstrated by using the ISAba1 forward primer and the
blaOXA-23-like, blaOXA-24-like, and blaOXA-51-like reverse prim-
ers, respectively.24
The reaction mixtures (50 ml volumes) contained 75mM
Tris-HCl (pH 8.8 at 25C), 20mM (NH4)2SO4, 0.01% (v/v)
Tween 20, 100nM dNTPs, 2.5mM MgCl2, 500nM of each
primer, 0.4U Taq DNA polymerase (Thermo Scientific), and
5ml DNA template. The PCR conditions (thermocycler; Bio-
metra) were initial denaturation at 94C for 5min, followed by
30 cycles of 25 sec at 94C, 40 sec at 57C, 50 sec at 72C, and
a final extension cycle of 5min at 72C.8,25 Positive controls of
blaoxa-23-like, blaoxa-24-like, and blaOXA-58-like and a negative
control were included in each PCR run.
Pulsed-field gel electrophoresis
Genetic diversity determinations of the A. baumannii-
calcoaceticus complex isolates were carried out by using
pulsed-field gel electrophoresis (PFGE). DNA fragments
obtained after restriction enzyme digestion were separated
by making use of the CHEF Mapper DRII apparatus (Bio-
Rad Laboratories). Colonies picked from blood agar plates
were embedded in 0.5% low melting point InCert agarose
(FMC Bioproducts) buffered in 5mM Tris-HCl pH 8.0,
50mM Na2EDTA, and 5mM EGTA. The blocks were de-
proteinated by overnight incubation in the same buffer con-
taining 1% sodium dodecyl sulfate and 1mg/mLof proteinase
K (Sigma Chemicals) at 37C. After extensive washing,
blocks were stored at 4C. Approximately 3 · 5mm portions
of the blocks were incubated in the presence of 30 units of the
restriction endonuclease ApaI (Boehringer Mannheim) in an
appropriate buffer. Incubation at 37C continued for 18 hrs,
628 GANJO ET AL.
after which the blocks were incorporated in 1% Seakem GTG
agarose slabgels (FMC BioProducts). The restriction frag-
ments were separated at a field strength of 6V/cm for 22 hrs at
14C. The pulse time linearly increased from 5 to 35 sec
during electrophoresis.26 Concatemers of lambda DNA were
used as molecular size markers (Bio-Rad). Gels were stained
with ethidium bromide postelectrophoresis and photographed27
(Mitsubishi Copy Processor, Progress Control, Waalwijk, The
Netherlands).The PFGE banding patterns were subsequently
analyzed by making use of BioNumerics software (version 7.1;
Applied Maths). A dendrogram was produced using the Dice
coefficient and an unweighted-pair group method using arith-
metic averages (UPGMA). Band tolerance was set at 1.0%.
Cluster designation was based on isolates showing approxi-
mately 85% or greater relatedness.
Whole genome sequencing and assembly
Genomic DNA of 15 isolates was extracted (DNeasy
Blood and Tissue Kit; Qiagen) and fragment libraries con-
structed using the Nextera Kit (Illumina) followed by 251-
bp paired-end sequencing (MiSeq; Illumina) according to
the manufacturer’s instructions.
The paired-end Illumina data were assembled using a
pipeline based on SPAdes 3.5.0. (http://bioinf.spbau.ru/en/
spades) with settings for Illumina 250 bp reads.
Multilocus sequence typing
Multilocus sequence typing (MLST) was performed from
the whole genome sequences of a subset of 15 isolates using
the MLST database (obtained on 2015-June-17), (https://
github.com/tseemann/mlst). Two different MLST schemes
were used: Oxford’s MLST and Pasteur’s MLST (http://
pubmlst.org/abaumannii).
A minimum of one isolate per PFGE cluster was selected
for MLST analysis. In case of more than 10 isolates per
PFGE cluster, a second or even a third isolate from the same
PFGE cluster was included for MLST analysis.
Resistance gene finding
In silico resistance gene finding was done on the assem-
bled genomic DNA using ResFinder-2.1 (https://cge.cbs.
dtu.dk//services/ResFinder/) with 98% identity threshold
and default for the remaining settings. ResFinder detects the
presence of resistance genes, but the functional integrity and
expression levels of resistance genes are not provided.
Results
Clinical bacterial strains
In the present study, 120 nonduplicate A. baumannii-
calcoaceticus complex isolates were collected from four
FIG. 1. Map of the city of Erbil with the respective hospitals, as indicated.
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hospitals in the Kurdistan region-Iraq: 34 isolates from
Rizgari teaching hospital, 43 from Rozhawa teaching hospi-
tal, 8 from Hawler teaching hospital, and 35 from Sulayma-
niyah teaching hospital. A. baumannii-calcoaceticus complex
isolates were cultured from various clinical specimens, in-
cluding urine n= 73 (61%), burn wounds n= 33 (27%), skin
and soft tissue n= 8 (7%), blood n= 2 (2%), sputum n=
2 (2%), and other specimens n= 2 (2%). A. baumannii-
calcoaceticus complex isolates were recovered from 37 men
(31%) and 83 women (69%). The median age of the patients
was 31 years and ranged from 2 to 78 years, see Table 1.
Antimicrobial resistance patterns
Of the 120 prospectively collected A. baumannii-
calcoaceticus complex isolates, susceptibility determi-
nations were performed by disk diffusion. One hundred
ten isolates were determined as carbapenem resistant. In
addition to the high prevalence of resistance to carbape-
nem antibiotics, most of the isolates also showed resis-
tance to other antibiotics such as tobramycin (95%) and
ciprofloxacin (89%).
Characterization mechanism(s)
of carbapenem resistance
As the resistance to carbapenems in A. baumannii is of-
ten due to the presence of additional blaOXA genes, besides
the already present blaOXA-51-like, the isolates were first
screened by PCR for the most prevalent blaOXA genes, that
is, blaOXA-23-like, blaOXA-24-like, and blaOXA-58-like. The ma-
jority (n= 101) of the carbapenem-resistant isolates (n= 110)
harbored the blaOXA-23-like gene (84.1%). Of the remaining 9
carbapenem-resistant isolates that were blaOXA-23-like negative,
four were positive for blaOXA-24-like. BlaOXA-58-like could not be
demonstrated in any of the isolates.
As the presence of an insertion sequence upstream of the
blaOXA gene can affect the expression of the additional
blaOXA gene, a PCR was performed for ISAba1. The ISAba1
was detected in 116 (96.6%) isolates. All blaOXA-23-like-
positive isolates (n= 101) showed a fragment of 1.6 kb using
the ISAba1 forward and blaOXA 23-like reverse primer. Three
of the four blaOXA-24-like-positive isolates were also positive for
ISAba1, but we did not succeed in demonstrating its upstream
localization of the blaOXA-24-like gene. The blaOXA-24-like isolate
missing the insertion element had MICs for imipenem and
meropenem of 8 and 16mg/ml, respectively. The three isolates
containing both the blaOXA-24-like and the ISAba1 had MICs of
‡32mg/ml for both imipenem and meropenem.
For the five remaining isolates, negative for blaOXA-23-like
and blaOXA-24-like, a PCR with the ISAba1 forward and
blaOXA-51-like reverse primer was conducted and all five
showed the presence of the ISAba1 1,100 bp upstream of the
blaOXA-51-like gene. The MICs for imipenem and meropenem
were, respectively, 4–8mg/ml for imipenem and 2–8 mg/ml
for meropenem. The ISAba1 insertion element was also
demonstrated in 7 of the 10 susceptible isolates.
PFGE analysis
As the majority of the isolates demonstrated the presence
of the blaOXA-23-like gene in combination with the ISAba1
insertion element, a high similarity was expected between
the different isolates. In the PFGE analysis (Fig. 2), clonal
relatedness was based on a cutoff value of 85%. The number
of isolates per cluster ranged from 3 to15. The rest, n = 39,
of the isolates were unique isolates. The isolates were dis-
tributed over eight clusters, represented by A to H. In Ta-
ble 2, the epidemiological relatedness of patients (location
and time) from whom isolates belonged to one of these eight
PFGE clusters is shown per cluster. When combining the
data from PFGE with the space-time information, cross-
transmission has likely occurred in three hospitals (Rozha-
wa, Hawler, and Sulaymaniyah). In the Rizgari hospital, six
isolates belonged to the PFGE cluster E and were from
the Urology Department, but the correlation in time could
not be made. The three largest clusters with likely cross-
transmission were detected in a 3-month period in the Urol-
ogy ward of the Sulaymaniyah hospital, with PFGE cluster D
(15 isolates), cluster B (7 isolates), and cluster G (7 isolates)
involved. In the Burn unit of the Rozhawa hospital, we could
detect five smaller clusters with likely cross-transmission,
with PFGE cluster C (3 isolates), cluster A (two events with
two isolates), cluster B (two isolates), and cluster H (two
isolates) involved. In cluster F, two isolates from the RCU
were isolated at the same time, indicating possible transmis-
sion in the Hawler hospital. Interestingly, all clusters except
cluster E harbored isolates from more than one hospital.
MLST
To be able to compare the typing data to other worldwide
clones, we have performed MLST analysis on a subset of
isolates (n = 15). Using the Pasteur scheme, the 15 isolates
belonged to six STs (ST2, ST94, ST136, ST623, ST792, and
ST793). According to the Oxford MLST typing scheme,
also six different ST types were determined (ST195, ST387,
ST441, ST460, ST1092, and ST1093).
The two representative isolates belonging to PFGE cluster
E and F belong to ST2 and in fact represent the European
clone II and worldwide lineage. By using the Oxford MLST
typing scheme, the two representative isolates of cluster A
were divided into two ST clones 1092 and 460. The two
isolates with ST1092 were collected at the same time from
two patients admitted to the Burn unit of the Rozhawa
hospital (isolate number 24 and 25; Table 2). Identical ST-
136 (Pasteur) or ST 1092 (Oxford) type were also demon-
strated in the Sulaymaniyah hospital. The same goes for
ST-793 (Pasteur), which was demonstrated in isolates not
only from Rozhawa but also from Sulaymaniyah hospital.
Also, identical STs, that is, 623 (Pasteur) were found in the
Rizgari and Sulaymaniyah hospital (Table 3).
Additional mechanisms of resistance
As we obtained the MLST results by whole genome se-
quencing, we were also able to detect additional mecha-
nisms of resistance present in the selected 15 isolates
(Table 3). Besides the blaOXA-23 gene, already detected by
PCR, additional variants of the blaOXA-51-like gene such as
blaOXA-91, blaOXA-66, and blaOXA-69, a variant of the chro-
mosomal encoded AmpC-gene, that is, blaADC-25-like, and
several aminoglycoside-modifying enzymes, as well as
sulfamethoxazole and tetracycline resistance genes, were
detected.
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Table 1. Characteristics of the 120 Acinetobacter baumannii-calcoaceticus Complex Isolates
Number Hospitals City Specimen date Gender Age Dept.
1B Rozhawa Erbil 17-10-2012 Female 25 y Burn unit
2 Rozhawa Erbil 23-10-2012 Female 15 y Burn unit
3A Rozhawa Erbil 18-12-2012 Female 14 y ICU
4A Rozhawa Erbil 27-11-2012 Female 14 y Burn unit
4B Rozhawa Erbil 27-11-2012 Female 24 y Burn unit
6A Rozhawa Erbil 30-11-2012 Female 69 y Burn unit
9A Hawler Erbil 25-11-2012 Male 17 y Emergency
13A Rozhawa Erbil 22-11-2012 Female 28 y Burn unit
15 Rozhawa Erbil 1-8-2013 Male 18 y Burn unit
16 Rozhawa Erbil 1-8-2013 Female 5 y Burn unit
17 Rozhawa Erbil 1-11-2013 Female 20 y Burn unit
20A Rozhawa Erbil 28-1-2013 Female 32 y Burn unit
21 Rizgari Erbil 15-9-2012 Female 48 y Surgery
22 Rizgari Erbil 11-12-2012 Female 20 y Surgery
23 Rizgari Erbil 26-2-2013 Female 31 y Internal medicine
24 Rozhawa Erbil 17-7-2012 Female 31 y Burn unit
25 Rozhawa Erbil 19-7-2012 Female 38 y Burn unit
26 Hawler Erbil 17-7-2012 Female 23 y Burn unit
27 Rozhawa Erbil 7-1-2012 Female 22 y Surgery
31 Rozhawa Erbil 22-7-2012 Female 24 y Burn unit
32 Rozhawa Erbil 8-12-2012 Female 25 y Burn unit
33 Rozhawa Erbil 8-12-2012 Female 16 y ICU
35A Rozhawa Erbil 8-2-2012 Male 16 y Neurology ICU
36A Rozhawa Erbil 8-2-2012 Male 19 y Neurology ICU
38B Rozhawa Erbil 18-8-2012 Female 19 y Burn unit
39 Rozhawa Erbil 18-8-2012 Female 58 y Burn unit
41 Rozhawa Erbil 9-2-2012 Male 44 y Burn unit
43 Rozhawa Erbil 9-9-2012 Male 25 y Internal medicine
46 Rozhawa Erbil 28-9-2012 Male 31 y ?
48 Hawler Erbil 9-9-2012 Female 15 y Orthopedics
50 Rozhawa Erbil 30-9-2012 Female 56 y Burn unit
20PS Rizgari Erbil 30-1-2013 Male 77 y Surgery
25PS Rizgari Erbil 2-3-2013 Female 17 y RCU
33PS Rozhawa Erbil 2-3-2012 Female 8 y ICU
41PS Rozhawa Erbil 31-1-2012 Male 2 y ICU
44PS Rozhawa Erbil 2-11-2012 Male 11 y Burn unit
57PS Rozhawa Erbil 3-9-2012 Male 22 y Burn unit
63PS Rozhawa Erbil 3-10-2012 Female 42 y Burn unit
79PS Hawler Erbil 21-4-2012 Male 16 y Surgery
97PS Hawler Erbil 14-5-2012 Female 15 y Ear Nose and Throat
100E-PS Rozhawa Erbil 5-12-2012 Female 16 y Burn unit
101PS Rozhawa Erbil 16-5-2012 Female 78 y Burn Unit
113PS Hawler Erbil 18-6-2012 Male 78 y RCU
114PS Hawler Erbil 16-6-2012 Male 41 y RCU
134PS Rozhawa Erbil 7-5-2012 Male 38 y
140PS Rozhawa Erbil 29-7-2012 Female 33 y Burn unit
148PS Hawler Erbil 23-8-2012 Male 48 y
150PS Rizgari Erbil ? Male 59 y Urology
157PS Rizgari Erbil 18-8-2012 Male 20 y Surgery
186PS Rozhawa Erbil 12-12-2012 Female 34 y Burn unit
B1 Rozhawa Erbil 9-1-2013 Female 16 y Burn unit
B2 Rozhawa Erbil 9-11-2013 Female 62 y Burn unit
B3 Rizgari Erbil 9-11-2013 Male 17 y RCU
B4 Rozhawa Erbil 9-11-2013 Female 36 y Burn unit
B5-1 Rozhawa Erbil 9-11-2013 Female 36 y Burn unit
B5-2 Rozhawa Erbil 9-11-2013 Female 11 y Burn unit
B6 Rozhawa Erbil 9-11-2013 Male 26 y Burn unit
B7 Rozhawa Erbil 10-2-2013 Female 25 y Burn unit
B8 Rozhawa Erbil 10-2-2013 Female 59 y Burn unit
B9 Rizgari Erbil 9-12-2013 Female 15 y ?
DL-1 Sulemani Sulaimania April 1st-June 30th 2012 Female 33 y Urology
DL-2 Sulemani Sulaimania April 1st-June 30th 2012 Female 18 y Urology
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Table 1. (Continued)
Number Hospitals City Specimen date Gender Age Dept.
DL-3 Sulemani Sulaimania April 1st-June 30th 2012 Female 56 y Urology
DL-4 Sulemani Sulaimania April 1st-June 30th 2012 Female 51 y Urology
DL-5 Sulemani Sulaimania April 1st-June 30th 2012 Female 24 y Urology
DL-6 Sulemani Sulaimania April 1st-June 30th 2012 Female 17 y Urology
DL-7 Sulemani Sulaimania April 1st-June 30th 2012 Female 16 y Urology
DL-8 Sulemani Sulaimania April 1st-June 30th 2012 Female 69 y Urology
DL-10 Sulemani Sulaimania April 1st-June 30th 2012 Female 48 y Urology
DL-11 Sulemani Sulaimania April 1st-June 30th 2012 Female 12 y Urology
DL-12 Sulemani Sulaimania April 1st-June 30th 2012 Female 33 y Urology
DL-14 Sulemani Sulaimania April 1st-June 30th 2012 Female 26 y Urology
DL-17 Sulemani Sulaimania April 1st-June 30th 2012 Female 59 y Urology
DL-18 Sulemani Sulaimania April 1st-June 30th 2012 Female 42 y Urology
DL-19 Sulemani Sulaimania April 1st-June 30th 2012 Female 32 y Urology
DL-20 Sulemani Sulaimania April 1st-June 30th 2012 Female 14 y Urology
DL-21 Sulemani Sulaimania April 1st-June 30th 2012 Female 29 y Urology
DL-22 Sulemani Sulaimania April 1st-June 30th 2012 Female 11 y Urology
DL-23 Sulemani Sulaimania April 1st-June 30th 2012 Female 44 y Urology
DL-24 Sulemani Sulaimania April 1st-June 30th 2012 Female 20 y Urology
DL-25 Sulemani Sulaimania April 1st-June 30th 2012 Female 51 y Urology
DL-26 Sulemani Sulaimania April 1st-June 30th 2012 Female 24 y Urology
DL-30 Sulemani Sulaimania April 1st-June 30th 2012 Female 15 y Urology
DL-31 Sulemani Sulaimania April 1st-June 30th 2012 Female 25 y Urology
DL-32 Sulemani Sulaimania April 1st-June 30th 2012 Female 12 y Urology
DL-33 Sulemani Sulaimania April 1st-June 30th 2012 Female 63 y Urology
DL-36 Sulemani Sulaimania April 1st-June 30th 2012 Female 23 y Urology
DL-37 Sulemani Sulaimania April 1st-June 30th 2012 Female 11 y Urology
DL-38 Sulemani Sulaimania April 1st-June 30th 2012 Female 27 y Urology
DL-39 Sulemani Sulaimania April 1st-June 30th 2012 Female 24 y Urology
DL-40 Sulemani Sulaimania April 1st-June 30th 2012 Female 18 y Urology
DL-41 Sulemani Sulaimania April 1st-June 30th 2012 Female 32 y Urology
DL-42 Sulemani Sulaimania April 1st-June 30th 2012 Female 47 y Urology
DL-43 Sulemani Sulaimania April 1st-June 30th 2012 Female 55 y Urology
DL-134 Sulemani Sulaimania April 1st-June 30th 2012 Female 36 y Urology
AB-1 Rizgari Erbil January 1st-April 30th 2013 Female 13 y Urology
AB-2 Rizgari Erbil January 1st-April 30th 2013 Female 42 y Urology
AB-3 Rizgari Erbil January 1st-April 30th 2013 Male 16 y Urology
AB-4 Rizgari Erbil January 1st-April 30th 2013 Male 21 y Urology
AB-5 Rizgari Erbil January 1st-April 30th 2013 Female 18 y Urology
AB-6 Rizgari Erbil January 1st-April 30th 2013 Female 22 y Urology
AB-7A Rizgari Erbil January 1st-April 30th 2013 Female 32 y Urology
AB-7B Rizgari Erbil January 1st-April 30th 2013 Female 19 y Urology
AB-8 Rizgari Erbil January 1st-April 30th 2013 Male 11 y Urology
AB-10 Rizgari Erbil January 1st-April 30th 2013 Female 52 y Urology
AB-11 Rizgari Erbil January 1st-April 30th 2013 Female 44 y Urology
AB-12B Rizgari Erbil January 1st-April 30th 2013 Male 10 y Urology
AB-13 Rizgari Erbil January 1st-April 30th 2013 Female 22 y Urology
AB-14B Rizgari Erbil January 1st-April 30th 2013 Female 35 y Urology
AB-15 Rizgari Erbil January 1st-April 30th 2013 Female 21 y Urology
AB-16 Rizgari Erbil January 1st-April 30th 2013 Female 63 y Urology
AB-17 Rizgari Erbil January 1st-April 30th 2013 Female 39 y Urology
AB-18 Rizgari Erbil January 1st-April 30th 2013 Female 32 y Urology
AB-19 Rizgari Erbil January 1st-April 30th 2013 Female 16 y Urology
AB-20 Rizgari Erbil January 1st-April 30th 2013 Female 23 y Urology
AB-21 Rizgari Erbil January 1st-April 30th 2013 Female 51 y Urology
AB-22 Rizgari Erbil January 1st-April 30th 2013 Male 37 y Urology
AB-23 Rizgari Erbil January 1st-April 30th 2013 Male 9 y Urology
AB-24 Rizgari Erbil January 1st-April 30th 2013 Female 28 y Urology
AB-26 Rizgari Erbil January 1st-April 30th 2013 Female 11 y Urology
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FIG. 2. PFGE dendrogram of ApaI di-
gested genomic DNA from 120 Acineto-
bacter baumannii-calcoaceticus complex
isolates. Cluster analysis of 120 Acineto-
bacter baumannii-calcoaceticus complex
isolates by using the Dice coefficient and
an unweighted-pair group method using
arithmetic averages (UPGMA). All iso-
lates depicted in the figure are unique
isolates collected from patients admitted
>48 hrs to one of the four teaching hospi-
tals, Rizgari, Hawler, Rozhawa and Sule-
mani. The number of isolates per cluster
are indicated in the boxes. The 15 isolates
used for additional MLST typing are
indicated by arrows. MLST, multilocus
sequence typing; PFGE, pulsed-field gel
electrophoresis.
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Discussion
In this study, we collected A. baumannii-calcoaceticus
complex isolates from four hospitals in Kurdistan region-Iraq
and investigated the molecular mechanism of carbapenem
resistance and the clonal relatedness. Although Hujer et al.22
already reported in 2006 that various resistance mechanisms
were present in Acinetobacter sp. isolates from military and
civilian patients injured in Iraq and Afghanistan, and treated
in a facility in Washington D.C., our report is the first on-site
multicenter survey in this specific region of Iraq.
From a total of 120 isolates of A. baumannii-
calcoaceticus complex, 110 (92%) were resistant to the last
resort antibiotics imipenem and meropenem. These data are
in accordance with reports from other countries in the
Middle East, such as the report by Sharif et al.28 that
demonstrated resistance rates of 86% and 82% for imipenem
and meropenem of A. baumannii isolates in Iran, respec-
tively.28 Similar observations have been made in other
countries describing the dissemination of carbapenem-
resistant A. baumannii isolates.27,29
Many mechanisms of resistance for imipenem in
A. baumannii have been described as the overproduction of
acquired blaOXA genes such as blaOXA-23-like, blaOXA-24-like,
blaOXA-58-like
15 or the presence of VIM and NDM genes.30
The majority of the isolates in the present study carried a
blaOXA-23-like gene. No isolate contained a blaOXA-58-like
gene; only in four isolates the presence of blaOXA-24-like was
demonstrated. These results are comparable with the results
of Mendes et al. who demonstrated that blaOXA-24/40 and
blaOXA-58 were less common in isolates recovered from six
countries.31
In our study, 96.6% of A. baumannii-calcoaceticus
complex isolates also carried the ISAba1 insertion element.
In the blaOXA-23-like-positive isolates, the ISAba1 was shown
to be located 1,600 bp upstream of the blaOXA23-like gene
located and thereby enhancing the upregulation of the
blaOXA-23-like gene. In the 5 isolates negative for blaOXA-23-like,
we were able to demonstrate the localization of the ISAba1
element upstream of the blaOXA-51-like gene, indicating that
the resistance for imipenem and meropenem could be due to
the overproduction of blaOXA-51-like. However, as we did not
Table 2. Analysis of the Epidemiological Relatedness of Patients (Location and Time)
from Whom Isolates Belonged to One of the Eight PFGE Clusters, Shown per Cluster
PFGE cluster
(no. of isolates)
Hospital (no.
of isolates)
Ward (no. of
isolates)
No. of isolates recovered
<3 monthsa (isolate numbers)
Month(s) with likely
cross-transmission
A (8) RoH (7) Burn unit (5) 2 (24b, 25) July 2012
2 (15, 16) August 2013
Neurology ICU (2) 2 (35A, 36A) February 2012
HaH (1) Burn unit (1) n.a.
B (13) SuH (7) Urology (7) 7 (DL-3, DL-20, DL-30, DL-33,
DL-38, DL-41, DL-43)
April–June 2012
RzH (3) RCU (1) n.a.
Urology (1) n.a.
Unknown (1) n.a.
RoH (2) Burn unit (2) 2 (B2, B6) November 2013
C (9) RoH (6) Burn unit (3) 3 (57PS, 63PS, 140PS) July–October 2012
ICU (2) 2 (33PS, 41PS) January–March 2012
Unknown (1) n.a.
RzH (1) Surgery (1) n.a.
HaH (1) Surgery (1) n.a.
SuH (1) Urology (1) n.a.
D (15) SuH (14) Urology (14) 14 (DL-1, DL-4, DL-5, DL-21, DL-22,
DL-23, DL-24, DL-25, DL-26,
DL-32, DL-36, DL-37, DL-42, DL-43)
April–June 2012
RzH (1) Urology (1) n.a.
E (6) RzH (6) Urology (6) Unknown
F (5) HaH (3) RCU (2) 2 (113PS, 114PS) June 2012
Unknown (1) n.a.
RoH (1) ICU (1) n.a.
RzH (1) RCU (1) n.a.
G (8) SuH (7) Urology (7) 7 (DL-6, DL-7, DL-11, DL-14,
DL-31, DL-39, DL-40)
April–June 2012
RzH (1) Urology n.a.
H (3) RoH (2) Burn unit (2) 2 (44PS, 100E-PS) November–
December 2012
HaH (1) ENT (1) n.a.
aA period of 3 months is taken in accordance to the definitions of epidemiological relatedness as described by Voor in ‘t holt et al.39
bIsolate numbers in bold indicate that isolates were subjected to MLST analysis.
ENT, Ear, Nose, and Throat; HaH, Hawler teaching hospital; MLST, multilocus sequence typing; n.a., not applicable; no., number; RoH,
Rozhawa teaching hospital; RzH, Rizgari teaching hospital; SuH, Sulaymaniyah teaching hospital; PFGE, pulsed-field gel electrophoresis.
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check for additional carbapenemases such as KPC, NDM, or
VIM, the increased MICs for imipenem and meropenem
could also be due to the previously mentioned mechanisms.
The same goes for the blaOXA-24-like-positive isolates in
which also a combination of the OXA enzyme with, for
instance, reduced membrane permeability and/or efflux
could explain the increased MICs for the carbapenem anti-
biotics.
Several other studies demonstrated the same findings on a
worldwide scale.32,33
With PCR, only specific genes will be detected, whereas
by WGS, all resistance genes can be demonstrated as long as
the sequence is present in the database. As WGS was used to
extract MLST data, we were also able to, at least for the 15
selected isolates, determine additional resistance genes.
ResFinder analysis of the WGS data identified and
confirmed the presence of the blaOXA-23 in all 15 isolates.
Furthermore, variants of the blaoxa-51 group were identi-
fied as blaOXA-66, blaOXA-69, and blaOXA-91-like (Table 3).
To our knowledge, blaOXA-69 and blaOXA-91 are rare. Be-
sides the OXA variants, also an AmpC variant described
as blaADC-25-like was demonstrated.
34 In addition to these
b-lactamase variants, several aminoglycoside-modifying
enzymes, tetracycline and sulfamethoxazole genes were
demonstrated, providing evidence for the MDR character
of these isolates.
Using PFGE typing, which is still considered a good
typing method for local outbreaks, we showed multiple
clusters of clonally related isolates from patients who were
epidemiologically related. These results are indicative for
cross-transmission. To prevent further transmission of these
MDR A. baumannii strains, intensified infection control
measures need to be taken, in addition to an antibiotic
stewardship program.35 Since identical clones were found in
multiple hospitals, these measures should ideally be carried
out in a program of regional collaboration.
With respect to the genetic relatedness, it has been dem-
onstrated in several studies that the presence of blaOXA-23-like is
often correlated with international clones I and II.20 This
suggests dissemination of one clone of blaOXA-23-like carbape-
nemase producers,36 but besides the presence in international
clones, numerous reports have also reported the presence of
blaOXA-23-like in different ST types.
20
In the present study, we were able to demonstrate the
presence of the international clone ST 2 (Pasteur) in isolates
obtained from the Rizgari hospital, but also different ST
types were obtained. These findings confirm that OXA-23 is
not restricted to one ST but that it is found in different ST
types, which is not that surprising as OXA-23 is an acquired
mechanism of resistance.
Our results are in accordance with the carbapenem-
resistant A. baumannii epidemic clusters fueled by the
spread of successful clones spreading among different cities
and countries.37,38
In conclusion, our present results reveal that MDR
A. baumannii-calcoaceticus complex isolates are spreading
also in the Kurdistan region.
PFGE and MLST results demonstrate that identical clones
are present in different hospitals. Surveillance cultures and
prudent use of antibiotics accompanied with proper guid-
ance and implementation of strict hygiene rules may reduce
further spread of resistant bacteria.
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